Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment and diagnosis of cancer and viral infections. Its products in clinical-stage development include bavituximab, a phosphatidylserine-targeting antibody, which is in Phase II clinical trials for the treatment of front-line and second-line non-small cell lung cancer (NSCLC), and pancreatic cancer; and Cotara, a DNA/histone-targeting antibody that is in Phase II clinical trial for the treatment of recurrent glioblastoma multiforme. The company is also developing bavituximab in combination with ribavirin, which is in Phase II clinical trial for the treatment of patients with genotype-1 hepatitis C virus infection. In addition, it has investigator-sponsored trial programs that evaluate bavituximab for the treatment of patients with liver cancer, second-line castration resistant prostate cancer, HER-2 negative metastatic breast cancer, and locally advanced or metastatic NSCLC. Further, the company, through its wholly-owned subsidiary, Avid Bioservices, Inc., offers integrated current good manufacturing practice (cGMP) commercial and clinical manufacturing services in the United States, including contract manufacturing of antibodies, recombinant proteins, and enzymes; cell culture development; process development; and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has license, research, and development agreements with the University of Texas Southwestern Medical Center at Dallas; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. focuses on selling its products in the United States and internationally in collaboration with marketing partners or through a direct sales force. The company was founded in 1981 and is based in Tustin, California.

Estadísticas clave